Real-World Efficacy of Nab-Paclitaxel Plus Capecitabine and a PD-1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer - PubMed
4 hours ago
- #PD-1 inhibitor
- #chemotherapy
- #esophageal cancer
- Combination of nab-paclitaxel, capecitabine, and PD-1 inhibitor shows efficacy in metastatic/locally advanced esophageal cancer.
- Median progression-free survival (PFS) was 24.7 months with 75% of patients responding to treatment.
- Objective response rate (ORR) was 66.7% in patients with measurable lesions.
- 6-month, 1-year, and 2-year PFS rates were 100%, 96.2%, and 67.9%, respectively.
- R0 resection rate was 77.8%, with pathological complete response (pCR) and major pathologic response (MPR) both at 66.7%.
- Most common adverse events were myelosuppression (27.8%) and liver dysfunction (25.0%).
- The regimen is a promising first-line or neoadjuvant treatment option for esophageal cancer.